VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 8, 2012) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, today issued an operational update on the commercialization of Verisante's Aura™, the innovative skin cancer detection device.
Installations of Beta Units have been completed at five leading dermatology clinics across Canada in Vancouver, Edmonton, Calgary, Oakville, Montreal and Markham. The Company continues to collect data from all sites for software verification purposes and has received valuable usability feedback.
In conjunction with the installations, the Company has completed technical training with Clarion Medical, the Company's exclusive Canadian distributor. Clarion's expert technicians will be responsible for the servicing of Aura™ in the field. Verisante also continues to work closely with Clarion and Bo-Pharma, the Company's Benelux distributor, to train sales staff and provide sales and marketing materials in preparation for product launch.
"Verisante has made great strides this year as we move closer towards full production and prepare to launch Aura™ in Canada and Europe," said Thomas Braun, President and CEO. "I am pleased with the recent media attention. And we continue to receive excellent feedback from both dermatologists and the general medical community as we look forward to making this life-saving technology available to healthcare professionals and their patients."
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, and Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. In addition, the Company was named a finalist for the 2011 Regional Awards for New Technology by the Canadian Manufacturers & Exporters and the National Research Council of Canada and named as the year's top ranking Technology and Life Sciences Company on the TSX Venture 50.
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.